AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ESPR
  4. [144] Esperion Therapeutics, Inc. SEC Filing

[144] Esperion Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Filing content is currently unavailable.

Source:

Stock ESPR logo
Esperion Therape

NASDAQ:ESPR

ESPR Rankings

#3403 Ranked by Market Cap
N/A Ranked by Dividends

ESPR Latest News

Aug 29, 2025
Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias
Aug 26, 2025
Esperion to Participate in Upcoming September Investor Conferences
Aug 7, 2025
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Aug 5, 2025
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
Jul 22, 2025
Esperion to Report Second Quarter 2025 Financial Results on August 5

ESPR Latest SEC Filings

Aug 13, 2025
[SCHEDULE 13G] Esperion Therapeutics, Inc. SEC Filing
Aug 13, 2025
[S-8] Esperion Therapeutics, Inc. Employee Benefit Plan Registration
Aug 13, 2025
[10-Q] Esperion Therapeutics, Inc. Quarterly Earnings Report
Aug 11, 2025
[NT 10-Q] Esperion Therapeutics, Inc. SEC Filing
Aug 11, 2025
[8-K/A] Esperion Therapeutics, Inc. Amends Material Event Report

ESPR Stock Data

439.54M
200.53M
0.56%
50.55%
11.55%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
United States
ANN ARBOR